EAM
NKTR icon

EverPoint Asset Management’s Nektar Therapeutics NKTR Stock Holding History

EverPoint Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,000
Closed -$1.29M – 491
2016
Q3 		$1.29M Sell
5,000
-18,333
-79% -$4.72M 0.02% 373
2016
Q2 		$4.98M Sell
23,333
-12,000
-34% -$2.68M 0.1% 228
2016
Q1 		$7.29M Buy
35,333
+8,666
+32% +$1.66M 0.14% 179
2015
Q4 		$6.74M Sell
26,667
-5,000
-16% -$1.03M 0.14% 198
2015
Q3 		$5.21M Buy
+31,667
New +$5.6M 0.14% 208

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EverPoint Asset Management's NKTR Position: Q4 2016 in Review

EverPoint Asset Management sold out of Nektar Therapeutics (NKTR) in Q4 2016, closing a stake of 5,000 shares — an estimated $1.29M sold.

EverPoint Asset Management first reported a position in NKTR in Q3 2015 and held it in 5 quarters. The position peaked at $7.29M in Q1 2016. 199 funds tracked by Wall St. Rank hold NKTR as of Q4 2016.

  • EverPoint Asset Management reported no remaining Nektar Therapeutics position as of Q4 2016 after selling out during the quarter.
  • EverPoint Asset Management sold 5,000 Nektar Therapeutics shares in Q4 2016, an estimated $1.29M.
  • EverPoint Asset Management first reported a position in Nektar Therapeutics in Q3 2015 and held it in 5 quarters.
  • EverPoint Asset Management's Nektar Therapeutics position peaked at $7.29M in Q1 2016.
  • 199 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.